A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection - Full Text View

A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection

This study has been completed.

Sponsored by:	Walter Reed Army Institute of Research (WRAIR)
Information provided by:	NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:	NCT00004579

Purpose

The purpose of this study is to see whether an HIV vaccine, ALVAC vCP205, is safe and can prevent HIV infection. The vCP205 vaccine will be tested with another vaccine, gp160MN/LAI-2.

Condition	Intervention	Phase
HIV Infections HIV Seronegativity	Biological: gp160 MN/LAI-2 Biological: ALVAC-HIV MN120TMG (vCP205)	Phase I

MedlinePlus related topics:

AIDS

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Double-Blind, Safety Study

Official Title:	A Phase I, Dose-Ranging Trial of the Pasteur Merieux Connaught (PMC) Oligomeric HIV-1 gp160MN/LAI-2 Vaccine Alone or Primed With Live Recombinant ALVAC-HIV (vCP205) in HIV Seronegative Adults

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Study Start Date:

April 1998

Detailed Description:

This study consists of 2 parts:

Part A: Dose-escalation protocol using oligomeric gp160MN/LAI-2. Part B: Placebo-controlled, randomized, double-blind (within arm) study of vCP205 priming with gp160MN/LAI-2 boosting.

Volunteers are followed for at least 1 year.

Eligibility

Ages Eligible for Study:	18 Years to 55 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria

Volunteers may be eligible for this study if they:

Are HIV-negative.
Are in good health.
Are between ages 18 and 55.
Are available for at least 1 year.
Are a resident of the United States of America.
Agree to practice sexual abstinence or use birth control.

Exclusion Criteria

Volunteers will not be eligible for this study if they:

Have ever been given an HIV vaccine or certain other vaccines. (However, rabies vaccines are allowed.)
Participate in activities that place them at high-risk for HIV infection, such as injection drug use or unprotected sex with someone who has HIV infection.
Have certain psychiatric, medical, or substance abuse problems.
Are allergic to eggs or other vaccines.
Are an employee at a participating site and have access to study information.
Are taking certain medications.
Have received blood transfusions within 3 months before entering this study.
Are pregnant or breast-feeding.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00004579

Locations


United States, Maryland
	Walter Reed Army Institute of Research
	Rockville, Maryland, United States

Sponsors and Collaborators

Walter Reed Army Institute of Research (WRAIR)

Investigators


Principal Investigator:	Jerome H. Kim

More Information

Publications:

Kim J, Robb M, Cox J, Ratto-Kim S, Vancott T, Zahwa H, Malia J, Chaddic C, El Habib R, Caudrelier P, Klein M, Excler JL, Birx D, McNeil J. Humoral and cellular HIV-specific responses induced by the prime-boost combination of Aventis-Pasteur ALVAC-HIV (vCP205) and oligomeric HIV-1 gp160MN/LAI-2 in HIV-uninfected adults. 8th Conf Retro and Opportun Infect. 2001 Feb 4-8 (abstract no 179)

Study ID Numbers:	RV124
First Received:	November 2, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00004579
Health Authority:	United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:

Vaccines, Synthetic

Viral Vaccines

HIV-1

Dose-Response Relationship, Drug

HIV Envelope Protein gp160

AIDS Vaccines

HIV Seronegativity

Avipoxvirus

Immunization

HIV Envelope Protein gp120

Recombination, Genetic

Study placed in the following topic categories:

Virus Diseases

Sexually Transmitted Diseases, Viral

HIV Infections

Sexually Transmitted Diseases

Acquired Immunodeficiency Syndrome

Retroviridae Infections

Immunologic Deficiency Syndromes

Additional relevant MeSH terms:

Communicable Diseases

RNA Virus Infections

Slow Virus Diseases

Immune System Diseases

Lentivirus Infections

Infection

ClinicalTrials.gov processed this record on October 07, 2008